Guo Tiantian, Gao Chong, Hao Jianhui, Lu Xiao, Xie Kun, Wang Xiaona, Li Jiaxuan, Zhou Han, Cui Wen, Shan Zhifu, Jiang Yanping, Qiao Xinyuan, Tang Lijie, Wang Li, Li Yijing
College of Veterinary Medicine, Northeast Agricultural University, Harbin, China.
Front Microbiol. 2022 Apr 4;13:872550. doi: 10.3389/fmicb.2022.872550. eCollection 2022.
The number of co-infections with multiple porcine diarrhea viruses has increased in recent years. Inducing mucosal immunity through oral immunization is an effective approach for controlling these pathogens. To generate a multi-pathogen vaccine against viral co-infection, we employed the vector platform, which was previously used to generate potent candidate vaccines against various diseases. Two strategies were used to test the protective efficiency of recombinant against multiple diarrhea viruses. First, we used a mixture of recombinant separately expressing antigens of transmissible gastroenteritis virus (TGEV), porcine epidemic diarrhea virus (PEDV), and porcine rotavirus (PoRV). Next, we used a recombinant expressing an antigen fusion protein of the above viruses. Twenty-four newborn piglets were divided into three groups and orally immunized with a mixture of recombinant , recombinant expressing the antigen fusion protein, or sterile phosphate-buffered saline daily for seven consecutive days after birth. After immunization, the piglets were randomly selected from each group for oral administration of PEDV, and these piglets were then cohabited with piglets without PEDV infection for 7 days. The protective effect against PEDV was evaluated based on clinical symptoms, viral shedding, and intestinal pathological damage. Piglets immunized with recombinant showed specific mucosal and humoral immune responses to the three viruses and were protected against severe diarrhea and intestinal pathology. Our results highlight the potential of an oral multi-pathogen vaccine based on to prevent transmission and limit the severity of viral co-infection.
近年来,多种猪腹泻病毒合并感染的情况有所增加。通过口服免疫诱导黏膜免疫是控制这些病原体的有效方法。为了研发一种针对病毒合并感染的多病原体疫苗,我们采用了先前用于研发针对各种疾病的有效候选疫苗的载体平台。使用了两种策略来测试重组体对多种腹泻病毒的保护效率。首先,我们使用了分别表达传染性胃肠炎病毒(TGEV)、猪流行性腹泻病毒(PEDV)和猪轮状病毒(PoRV)抗原的重组体混合物。其次,我们使用了表达上述病毒抗原融合蛋白的重组体。24只新生仔猪被分为三组,在出生后连续7天每天口服重组体混合物、表达抗原融合蛋白的重组体或无菌磷酸盐缓冲盐水。免疫后,从每组中随机选择仔猪口服PEDV,然后将这些仔猪与未感染PEDV的仔猪同居7天。根据临床症状、病毒排出情况和肠道病理损伤评估对PEDV的保护效果。用重组体免疫的仔猪对这三种病毒表现出特异性黏膜和体液免疫反应,并免受严重腹泻和肠道病理损伤。我们的结果突出了基于的口服多病原体疫苗在预防传播和限制病毒合并感染严重程度方面的潜力。